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SYMPOSIUM:
ELIMINATING LEGAL, REGULATORY, AND ECONOMIC
BARRIERS TO BIODEFENSE VACCINE DEVELOPMENT
INTRODUCTION

It is by now a troublesome cardinal tenet of the Nation's
counterterrorism policy that, "limited research, development, and
production capability for certain vaccines is one of the largest hurdles
currently facing military and civilian responders as they prepare for
biological threats."
Advisory Panel to Assess Domestic Response
Capabilities for Terrorism Involving Weapons of
Mass Destruction, Third Annual Report to the
President and the Congress vi (2001).
On September 11, 2001, the United States became acutely aware of its
vulnerability to terrorist attacks from above. While this attack was devastating, the
subsequent anthrax attacks shortly thereafter were perhaps equally unsettling,
reminding us of the potential destruction that may be wreaked by biological
terrorism. As a result of the first event, we now encounter security efforts to
prevent another air attack each time we go to an airport. As a result of the second,
the U.S. government, pharmaceutical companies, and research institutions have
begun to put into place initiatives that will help protect us from the intentional use
of biological or other dangerous pathogens. One component of these initiatives is
the development and distribution of vaccines that may be administered to military
and civilian populations in advance of, or in response to, a bioterrorist threat. The
development and administration of such vaccines, however, is fraught with
significant obstacles ranging from reluctance on the part of manufacturers to invest
in the development and production of a vaccine without assurances that their
intellectual property will be protected and that they will have a definite end user;
concerns on the part of manufactures about regulatory approvals and liability if a
vaccine has unanticipated side effects; concerns from public health officials about
their ability to vaccinate a sufficient number of the population for the vaccine to be
effective as well as their authority to forcefully vaccinate individuals under
emergency circumstances; and, lastly, fears of physicians, hospitals and other
health care providers over their liability in administering the vaccines.
This issue of the Journalof Health Care Law & Policy is devoted to these
concerns. The articles that appear in the issue are based on several papers that
were presented at a conference entitled "Eliminating Legal, Regulatory, and
Economic Barriers to Biodefense Vaccine Development," hosted by the
University of Maryland School of Law's Law & Health Care Program (L&HCP),
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the University's Center for Health and Homeland Security (CHHS), and the MidAtlantic Regional Center of Excellence for Biodefense and Emerging Infectious
Diseases (MARCE) on June 9, 2004. The conference brought together health
professionals in the fields of vaccine development, distribution, and administration,
as well as several public health experts to discuss the legal, regulatory, and
economic obstacles to biodefense vaccine development and distribution. Papers
delivered at the conference examined the financial market for vaccines, the role of
the U.S. Food and Drug Administration's regulatory process, intellectual property
issues, informed consent, and manufacturer and institutional liability in the
manufacture and distribution of biodefense vaccines. The symposium agenda
follows this introduction.
Contributors to this issue of the Journal include Michael Greenberger, Law
School Professor and Director, Center for Health and Homeland Security,
University of Maryland School of Law; Wendy E. Parmet, George J. and Kathleen
Waters Matthews University Distinguished Professor of Law, Northeastern
University School of Law; Gail H. Javitt, Adjunct Professor, University of
Maryland School of Law and Policy Analyst, Genetics and Public Policy Center,
Phoebe R. Berman Bioethics Institute, Johns Hopkins University; Cynthia M. Ho,
Clifford E. Vickrey Research Professor, Loyola University of Chicago School of
Law; and Elin Gursky, Principal Deputy for Biodefense at the National Strategic
Support Directorate of Analytic Services, Inc. (ANSER).
Perhaps one of the most significant obstacles to the development and
production of vaccines to protect against bioterrorist threats in the U.S. are
concerns of liability on the part of vaccine manufacturers. While the United States
has begun to implement a biodefense strategy that includes vaccine research,
development, and mass vaccination programs, the viability of these programs will
be in doubt if there is not adequate financial support to protect vaccine
manufacturers, sellers, and distributors from liability and to compensate those
injured by the vaccines. Professor Michael Greenberger addresses this problem in
his contribution to this issue of the Journal. His article details the inadequacy of
the federal liability and compensation scheme and its inability to effectively
remedy injuries stemming from the smallpox vaccine. Professor Greenberger
suggests that the problem is so critical to the Nation's protection in the event of a
biological or chemical attack that the United States government itself must
financially back a robust, well-tailored liability and compensation regime.
Another obstacle to biodefense vaccine development and administration is the
lengthy and complicated procedure by which new vaccines are approved by the
United States Food and Drug Administration. In her article, Gail H. Javitt
comments on the need for regulatory flexibility in the face of emergent threats. In
so doing, Professor Javitt reflects on the 1991 Gulf War and the actions of the
Department of Defense in obtaining regulatory approval to administer certain, as
yet unapproved vaccines, to members of the armed forces. While critics argue that
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such action constitutes prohibited human experimentation, she takes issue with that
claim. Instead, she proposes a clear line between research and treatment activities,
arguing that a vaccine's safety and effectiveness can be under investigation while it
is administered as a prophylactic or a therapy. Professor Javitt maintains that
people receiving such drugs should be fully informed of the risks, while arguing
that administering tentatively-approved vaccines and therapies will promote the
public health.
In a time of bioterrorist threat, public health authorities will be saddled with
the responsibility of distributing and administering vaccines to the civilian
population. While laws may allow for vaccination without consent in times of
medical emergency, public health authorities and bioethicists argue over whether
as a matter of public policy individuals should be forcibly vaccinated against their
will. Professor Wendy Parmet weighs in on this debate in her article, "Informed
Consent and Public Health: Are They Compatible When It Comes to Vaccines?"
She takes issue with the seemingly divergent notions that: 1) compulsory
vaccination should be authorized for the public health, and 2) no patient should be
vaccinated without giving informed consent. Rather, she argues that the two
notions are compatible, and contends that informed consent actually serves to
promote public health.
Another impediment to a viable vaccine industry is the high degree of legal
uncertainty over questions relating to who, in the long line of development of a
vaccine (from research to commercialization), actually "owns" (or has the
intellectual property interest in) a vaccine, i.e., who has the right to control and
reap financial reward for the vaccine discovery. In her article, Cynthia M. Ho
reviews the intellectual property issues surrounding the development of biodefense
vaccines, including the legal and political problems associated with compulsory
licensing of drugs such as Cipro, the only drug available to combat anthrax,
following September 11, 2001. Professor Ho examines the scope of intellectual
property rights to such vaccines under both domestic and international law, and
offers an analysis designed to afford the reader a proper understanding of both the
patent barriers to the development of biodefense vaccines and potential avenues to
avoid them.
In 2002, President Bush established the Phase I civilian smallpox vaccination
program, designed to vaccinate medical, public health, and other emergency
responders against the possible threat of a smallpox outbreak. In her article, Elin
Gursky, Sc.D., presents a case study of the Phase I civilian smallpox vaccination
program. She provides a fascinating historical perspective on the program and
describes the problems the program encountered based on an empirical survey of
public health authorities in states with high and low vaccination rates in the Phase I
program. Among the problems cited were lack of legal protections for vaccine
administrators and others involved in the process of screening, systemic failures,
and lack of funding to States to properly implement the program as mandated by
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the federal government. She expresses the hope that the lessons learned from the
Phase I civilian smallpox program will be applied to, and improve, ongoing
bioterrorism preparedness efforts.
Though not a presenter at the Symposium, Franklin H. Alden, Jr., a student at
the University of Maryland School of Law and Associate Editor for the Journalof
Health Care Law & Policy, contributes a thoughtful analysis of the Model State
Emergency Health Powers Act, and compares it to similar Maryland legislation.
Mr. Alden's article echoes a number of the sentiments expressed by other
Symposium authors by arguing that legislatures should carefully maintain the
personal liberties of citizens in the event of a health emergency.
The Journal of Health Care Law & Policy's foremost goal is to provide a
forum for the interdisciplinary discussion of leading issues in health law, policy,
and bioethics. In keeping with the Journal's goal, it is my hope that this issue
stimulates ideas and discussion on the topic of biodefense vaccine development for
all our readers. On behalf of the Journal of Health Care Law & Policy, I would
like to thank the sponsors and participants of the symposium for their contributions
and the staff, editorial board, and faculty advisors for their hard work and
dedication in producing this issue of our Journal.
Melanie Santiago
Editor in Chief
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SYMPOSIUM:
ELIMINATING LEGAL, REGULATORY, AND ECONOMIC
BARRIERS TO BIODEFENSE VACCINE DEVELOPMENT
AGENDA
Welcome and Introductions
Michael Greenberger,Director,Centerfor Health and Homeland
Security, University of Maryland
Diane Hoffman, Associate Dean andDirector,Law & Health Care
Program, UniversityofMarylandSchool of Law
DonaldBurke, Directorfor Immunization Research, Johns Hopkins
Bloomberg School of Public Health and Co-Directorof the Mid-Atlantic
Regional Center of ExcellenceforBiodefense and Emerging Infectious
Diseases (MARCE)
Challenges to the Development of a Vibrant Vaccine Industry
Lance K. Gordon, President, VaxGen, Inc.
Is Bioshield the Answer?
Philip Russell, SpecialAdvisor on Vaccine Development and
Production, Officeof Public Health Preparedness, US.
Department of Health and Human Services
The Role of the FDA
Margaret 0 'K. Glavin, Assistant Commissionerfor CounterTerrorism, US. Food and Drug Administration
The Need for Regulatory Flexibility in the Face of Emergent Threats
Gail H. Javitt,Adjunct Professor,University of MarylandSchool
of Law and Policy Analyst, Genetics and Public Policy Center,
Phoebe R. Berman Bioethics Institute,Johns Hopkins University
The Role of Intellectual Property Policy
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Cynthia M Ho, CliffordE. Vickrey Research Professor,Loyola
University School of Law, Chicago,IL
The NIH Biodefense Research Agenda
Ernest T Takafuji, Assistant Directorfor Biodefense Research, National
Institute ofAllergy and Infectious Diseases (NIAID)
Issues of Consent and Standard of Care in the Administration of
Vaccines in Response to a Bioterrorist Threat
Wendy E. Parmet,George J. and Kathleen Waters Matthews University
DistinguishedProfessorof Law, Northeastern University School of Law,
Boston, MA
The Smallpox Vaccination Project: A Case Study
Elin Gursky, Sc.D, PrincipalDeputyfor Biodefense, National Strategies
SupportDirectorate,Analystic Services, Inc. (ANSER)
Liability Issues Associated with Vaccine Development and Distribution
Michael Greenberger,Director, Centerfor Health and Homeland
Security, University oJMaryland
EdwardRichards, Harvey A. PeltierEndowed ProfessorandDirector,
Program in Law, Science and PublicHealth, Louisiana State University,
Baton Rouge, LA
William C. Bertrand,Jr., Vice-President,General Counsel and Corporate
ComplianceOfficer,Medlmmune

